Serum AMH in Physiology and Pathology of Male Gonads

Ewa Matuszczak, Adam Hermanowicz, Marta Komarowska, Wojciech Debek, Ewa Matuszczak, Adam Hermanowicz, Marta Komarowska, Wojciech Debek

Abstract

AMH is secreted by immature Sertoli cells (SC) and is responsible for the regression of Müllerian ducts in the male fetus as part of the sexual differentiation process. AMH is also involved in testicular development and function. AMHs are at their lowest levels in the first days after birth but increase after the first week, likely reflecting active SC proliferation. AMH rises rapidly in concentration in boys during the first month, reaching a peak level at about 6 months of age, and then slowly declines during childhood, falling to low levels in puberty. Basal and FSH-stimulated levels of AMH, might become a useful predictive marker of the spermatogenic response to gonadotropic treatment in young patients with hypogonadotropic hypogonadism. After puberty, AMH is released preferentially by the apical pole of the SC towards the lumen of the seminiferous tubules, resulting in higher concentrations in the seminal plasma than in the serum. Defects in AMH production and insensitivity to AMH due to receptor defects result in the persistent Müllerian duct syndrome. A measurable value of AMH in a boy with bilateral cryptorchidism is predictive of undescended testes, while an undetectable value is highly suggestive of anorchia or ovaries, as would be the case in girls with female pseudohermaphroditism and pure gonadal dysgenesis. Lower serum AMH concentrations in otherwise healthy boys with cryptorchidism, who were compared with their age-matched counterparts with palpable testes, have been reported previously. AMH levels are higher in prepubertal patients with varicocele than in controls. This altered serum profile of AMH in boys with varicoceles may indicate an early abnormality in the regulation of the seminiferous epithelial function. Serum AMH is known to be valuable in assessing gonadal function. As compared to testing involving the administration of human chorionic gonadotropin, the measurement of AMH is more sensitive and equally specific. Measurement of AMH is very useful in young children, because serum gonadotropin concentrations in those who are agonadal are nondiagnostic in midchildhood and serum testosterone concentrations may fail to increase with provocative testing in children with abdominal testes.

References

    1. Lee MM, Donahoe PK. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocrine Reviews. 1993;14(2):152–164.
    1. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Practice and Research Clinical Endocrinology and Metabolism. 2011;25(2):221–238.
    1. Rey R, Lukas-Croisier C, Lasala C, Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Molecular and Cellular Endocrinology. 2003;211(1-2):21–31.
    1. Taguchi O, Cunha GR, Lawrence WD, Robboy SJ. Timing and irreversibility of Mullerian duct inhibition in the embryonic reproductive tract of the human male. Developmental Biology. 1984;106(2):394–398.
    1. Bergadá I, Milani C, Bedecarrás P, et al. Time course of the serum gonadotropin surge, inhibins, and anti-Müllerian hormone in normal newborn males during the first month of life. Journal of Clinical Endocrinology and Metabolism. 2006;91(10):4092–4098.
    1. Lukas-Croisier C, Lasala C, Nicaud J, et al. Follicle-stimulating hormone increases testicular anti-Müllerian hormone (AMH) production through Sertoli cell proliferation and a nonclassical cyclic adenosine 5′-monophosphate-mediated activation of the AMH gene. Molecular Endocrinology. 2003;17(4):550–561.
    1. Al-Attar L, Noël K, Dutertre M, et al. Hormonal and cellular regulation of Sertoli cell anti-Mullerian hormone production in the postnatal mouse. The Journal of Clinical Investigation. 1997;100(6):1335–1343.
    1. Grumbach MM. Commentary: a window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. Journal of Clinical Endocrinology and Metabolism. 2005;90(5):3122–3127.
    1. Lee MM, Misra M, Donahoe PK, MacLaughlin DT. MIS/AMH in the assessment of cryptorchidism and intersex conditions. Molecular and Cellular Endocrinology. 2003;211(1-2):91–98.
    1. Hero M, Tommiska J, Vaaralahti K, et al. Circulating antimüllerian hormone levels in boys decline during early puberty and correlate with inhibin B. Fertility and Sterility. 2012;97(5):1242–1247.
    1. Tan KAL, De Gendt K, Atanassova N, et al. The role of androgens in sertoli cell proliferation and functional maturation: studies in mice with total or sertoli cell-selective ablation of the androgen receptor. Endocrinology. 2005;146(6):2674–2683.
    1. Boukari K, Meduri G, Brailly-Tabard S, et al. Lack of androgen receptor expression in sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development. Journal of Clinical Endocrinology and Metabolism. 2009;94(5):1818–1825.
    1. Aksglaede L, Sørensen K, Boas M, et al. Changes in anti-Müllerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. Journal of Clinical Endocrinology and Metabolism. 2010;95(12):5357–5364.
    1. Grinspon RP, Bedecarrás P, Ballerini MG, et al. Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in trisomy 21. International Journal of Andrology. 2011;34(5):e487–e498.
    1. Young J, Chanson P, Salenave S, et al. Testicular anti-Müllerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism. 2005;90(2):724–728.
    1. Eldar-Geva T, Liberty G, Chertin B, et al. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. European Journal of Endocrinology. 2010;162(1):177–181.
    1. Fujisawa M, Yamazaki T, Fujioka H, Takenaka A. Differential regulation of inhibin subunits by germ cells in human testes. Archives of Andrology. 2004;50(5):339–345.
    1. Nistal M, Abaurrea A, Paniagua R. Morphological and histometric study on the human Sertoli cell from birth to the onset of puberty. Journal of Anatomy. 1982;134(2):351–363.
    1. Chemes HE. Infancy is not a quiescent period of testicular development. International Journal of Andrology. 2001;24(1):2–7.
    1. Wreford NG, Kumar TR, Matzuk MM, de Kretser DM. Analysis of the testicular phenotype of the follicle-stimulating hormone β-subunit knockout and the activin type II receptor knockout mice by stereological analysis. Endocrinology. 2001;142(7):2916–2920.
    1. Pitteloud N, Hayes FJ, Boepple PA, et al. The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism. 2002;87(1):152–160.
    1. Teixeira J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocrine Reviews. 2001;22(5):657–674.
    1. Sinisi AA, Esposito D, Maione L, et al. Seminal anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. Human Reproduction. 2008;23(5):1029–1034.
    1. Hutson JM. Testicular feminization: a model for testicular descent in mice and men. Journal of Pediatric Surgery. 1986;21(3):195–198.
    1. Fujisawa M, Yamasaki T, Okada H, Kamidono S. The significance of anti-Müllerian hormone concentration in seminal plasma for spermatogenesis. Human Reproduction. 2002;17(4):968–970.
    1. Josso N, Rey R, Picard JY. Testicular anti-Mullerian hormone: clinical applications in DSD. Seminars in Reproductive Medicine. 2012;30(5):364–373.
    1. Josso N, Belville C, di Clemente N, Picard J-Y. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Human Reproduction Update. 2005;11(4):351–356.
    1. Kubini K, Zachmann M, Albers N, et al. Basal inhibin B and the testosterone response to human chorionic gonadotropin correlate in prepubertal boys. Journal of Clinical Endocrinology and Metabolism. 2000;85(1):134–138.
    1. Thompson ST, Grillis MA, Wolkoff LH, Katzin WE. Transverse testicular ectopia in a man with persistent mullerian duct syndrome. Archives of Pathology and Laboratory Medicine. 1994;118(7):752–755.
    1. Rey RA, Belville C, Nihoul-Fekete C, et al. Evaluation of gonadal function in 107 intersex patients by means of serum antiMüllerian hormone measurement. The Journal of Clinical Endocrinology & Metabolism. 1999;84:627–631.
    1. Werner R, Grötsch H, Hiort O. 46,XY disorders of sex development—the undermasculinised male with disorders of androgen action. Best Practice and Research Clinical Endocrinology and Metabolism. 2010;24(2):263–277.
    1. Belville C, Maréchal J-D, Pennetier S, et al. Natural mutations of the anti-Müllerian hormone type II receptor found in persistent Müllerian duct syndrome affect ligand binding, signal transduction and cellular transport. Human Molecular Genetics. 2009;18(16):3002–3013.
    1. Rey RA, Grinspon RP, Gottlieb S, et al. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology. 2013;1:3–16.
    1. Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. European Journal of Endocrinology. 2007;156(1):105–111.
    1. Coutant R, Biette-Demeneix E, Bouvattier C, et al. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. Journal of Clinical Endocrinology and Metabolism. 2010;95(12):5225–5232.
    1. Bougnères P, François M, Pantalone L, et al. Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. Journal of Clinical Endocrinology and Metabolism. 2008;93(6):2202–2205.
    1. Lee MM, Donahoe PK, Silverman BL, et al. Measurements of serum Müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. The New England Journal of Medicine. 1997;336:1480–1486.
    1. Gustafson ML, Lee MM, Scully RE, et al. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. The New England Journal of Medicine. 1992;326(7):466–471.
    1. Rey RA, Lhomme C, Marcillac I, et al. AntiMüllerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum α-inhibin and estradiol. American Journal of Obstetrics and Gynecology. 1996;174(3):958–965.
    1. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and functional aspects of testicular descent and cryptorchidism. Endocrine Reviews. 1997;18(2):259–280.
    1. Hutson JM, Hasthorpe S. Testicular descent and cryptorchidism: the state of the art in 2004. Journal of Pediatric Surgery. 2005;40(2):297–302.
    1. Adham IM, Agoulnik AI. Insulin-like 3 signalling in testicular descent. International Journal of Andrology. 2004;27(5):257–265.
    1. Nef S, Parada LF. Cryptorchidism in mice mutant for Insl3. Nature Genetics. 1999;22(3):295–299.
    1. Zimmermann S, Steding G, Emmen JMA, et al. Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Molecular Endocrinology. 1999;13(5):681–691.
    1. Overbeek PA, Gorlov IP, Sutherland RW, et al. A transgenic insertion causing cryptorchidism in mice. Genesis. 2001;30:26–35.
    1. Ferlin A, Bogatcheva NV, Gianesello L, et al. Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. Molecular Human Reproduction. 2006;12(6):401–406.
    1. Roh J, Virtanen H, Kumagai J, et al. Lack of LGR8 gene mutation in Finnish patients with a family history of cryptorchidism. Reproductive BioMedicine Online. 2003;7(4):400–406.
    1. Cortes D. Cryptorchidism—aspects of pathogenesis, histology and treatment. Scandinavian Journal of Urology and Nephrology. Supplementum. 1998;196:1–54.
    1. Engeler DS, Hösli PO, John H, et al. Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. Urology. 2000;56(1):144–148.
    1. Lee PA, O’Leary LA, Songer NJ, Coughlin MT, Bellinger MF, LaPorte RE. Paternity after unilateral cryptorchidism: a controlled study. Pediatrics. 1996;98(4):676–679.
    1. Thorup J, McLachlan R, Cortes D, et al. What is new in cryptorchidism and hypospadias—a critical review on the testicular dysgenesis hypothesis. Journal of Pediatric Surgery. 2010;45(10):2074–2086.
    1. Lee PA, Coughlin MT. Fertility after bilateral cryptorchidism. Evaluation by paternity, hormone, and semen data. Hormone Research. 2001;55(1):28–32.
    1. Matuszczak E, Hermanowicz A, Debek W, Oksiuta M, Dzienis-Koronkiewicz E, Zelazowska-Rutkowska B. Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life. Endocrine. 2012;41:334–337.
    1. Demircan M, Akinci A, Mutus M. The effects of orchiopexy on serum anti-Müllerian hormone levels in unilateral cryptorchid infants. Pediatric Surgery International. 2006;22(3):271–273.
    1. Guibourdenche J, Lucidarme N, Chevenne D, et al. Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical interest. Molecular and Cellular Endocrinology. 2003;211(1-2):55–63.
    1. Komarowska MD, Hermanowicz A, Matuszczak E, et al. Anti-Müllerian hormone levels in serum 1 year after unilateral orchiopexy. Journal of Pediatric Endocrinology & Metabolism. 2012;25(11-12):1073–1076.
    1. Aksglaede L, Christiansen P, Sørensen K, et al. Serum concentrations of anti-Müllerian hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. Acta Paediatrica. 2011;100(6):839–845.
    1. Trigo RV, Bergada I, Rey R, et al. Altered serum profile of inhibin B, pro-alphaC and anti-Müllerian hormone in prepubertal and pubertal boys with varicocele. Clinical Endocrinology. 2004;60:758–764.
    1. Goulis DC, Mintziori G, Koliakos N, et al. Inhibin B and anti-Müllerian hormone in spermatic vein of subfertile men with varicocele. Reproductive Sciences. 2011;18(6):551–555.
    1. Ahmed SF, Keir L, McNeilly J, Galloway P, O’Toole S, Wallace AM. The concordance between serum anti-Mullerian hormone and testosterone concentrations depends on duration of hCG stimulation in boys undergoing investigation of gonadal function. Clinical Endocrinology. 2010;72(6):814–819.
    1. Grinspon RP, Rey RA. Anti-Müllerian hormone and sertoli cell function in paediatric male hypogonadism. Hormone Research in Paediatrics. 2010;73(2):81–92.
    1. Lustig RH, Conte FA, Kogan BA, Grumbach MM. Ontogeny of gonadotropin secretion in congenital anorchism: sexual dimorphism versus syndrome of gonadal dysgenesis and diagnostic considerations. Journal of Urology. 1987;138(3):587–591.
    1. Cortes D. Cryptorchidism—aspects of pathogenesis, histology and treatment. Scandinavian Journal of Urology and Nephrology. Supplementum. 1998;196:1–54.
    1. Hadziselimovic F, Hoecht B. Testicular histology related to fertility outcome and postpubertal hormone status in cryptorchidism. Klinische Pädiatrie. 2008;220(5):302–307.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren